Skip to main content
Premium Trial:

Request an Annual Quote

Steve McPhail, Donald Holzworth, Michael Minas, Thomas Becker, Robert Rosenthal, Jim Lindelien, Roland Luethy, Peter Ehrenheim, Andrew Carr, William Castell


Steve McPhail has been named the new CEO of Expression Analysis, a microarray analysis firm, the Durham, NC, company said last week. He replaces Donald Holzworth, president and CEO of Analytical Sciences, who has acted as EA’s interim CEO since Sept. 2001 when ASI began incubating the company. Holzworth will now serve as chairman of EA’s board of directors.

Michael Minas has been appointed an interim member of MWG Biotech’s internal management board, and will serve on the board until May 21st, the company said this week. Minas has been head of MWG Biotech’s accounting and financial division since September 2001. He will serve with Thomas Becker, chairman of the board of management.

Robert Rosenthal, president and COO of Boston Life Sciences, has been named to the board of directors for Protedyne, a lab automation supplier for genomics, proteomics, and biopharmaceutical research, the company announced.

Jim Lindelien, founder and CTO of TimeLogic, is leaving the company “to pursue new opportunities,” the company said Feb. 27. Lindelien, who engineered the company’s bioinformatics solution DeCypher, will not be directly replaced, but Roland Luethy, the company’s senior bioinformatics research scientist, will head up future development of the DeCypher system, according to TimeLogic.

Peter Ehrenheim, who has directed Amersham Biosciences’ protein separations business as a vice president under president Andrew Carr, has been named president of protein separations, a new position, reporting to William Castell, the CEO of Amersham PLC, the company said last week.


The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.